FDA Expands Approval of Risankizumab for Pediatric Plaque Psoriasis and Psoriatic Arthritis

The FDA has approved risankizumab-rzaa (SKYRIZI; AbbVie) for children aged 6 and older with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy, as well as for those with active psoriatic arthritis (PsA). This makes risankizumab the first and only IL-23 inhibitor FDA-approved for children aged 6 and older under 40 kg with these conditions. A new 55 mg pre-filled syringe has been approved for patients weighing less than 40 kg.

Context

Risankizumab is an interleukin-23 (IL-23) inhibitor that has been previously approved for adult patients with similar conditions. The approval for pediatric use marks a milestone as it is the first IL-23 inhibitor available for children aged 6 and older who weigh less than 40 kg. This decision reflects ongoing efforts to address the unmet medical needs in pediatric dermatology and rheumatology.

Why it matters

The FDA's approval of risankizumab for pediatric patients represents a significant advancement in treatment options for children suffering from moderate to severe plaque psoriasis and psoriatic arthritis. This is particularly important as these conditions can severely impact the quality of life for young patients. By expanding access to effective therapies, the approval may lead to better management of symptoms and improved long-term outcomes for affected children.

Implications

The approval could lead to increased treatment options for pediatric patients, potentially reducing the burden of these chronic conditions. Families may experience improved health outcomes and quality of life for their children. Pharmaceutical companies may also be encouraged to invest in research and development for pediatric treatments in similar therapeutic areas.

What to watch

Healthcare providers may begin incorporating risankizumab into treatment plans for eligible pediatric patients. Monitoring of patient responses to the new therapy will be crucial in assessing its effectiveness and safety in younger populations. Additionally, further studies may emerge to explore the long-term effects of this medication in children.